{"id":58740,"date":"2024-01-18T19:03:26","date_gmt":"2024-01-18T18:03:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/"},"modified":"2024-01-18T19:03:26","modified_gmt":"2024-01-18T18:03:26","slug":"tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/","title":{"rendered":"Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium"},"content":{"rendered":"<div>\n<p>HOUSTON&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/BreastCancer?src=hash\" target=\"_blank\" rel=\"noopener\">#BreastCancer<\/a>&#8211;Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will present a trials in progress poster at the upcoming 2024 ASCO Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in San Francisco, CA. The poster will highlight the design of the ongoing REVERT <sub>LIVER CANCER<\/sub> study, a Phase 1b\/2 trial evaluating safety and clinical activity of TTI-101, a novel STAT3 inhibitor, as monotherapy and in combination with standard of care in patients with locally advanced or metastatic, and unresectable hepatocellular carcinoma (HCC).<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20240118383580\/en\/808014\/5\/Tvardi-Master_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240118383580\/en\/808014\/21\/Tvardi-Master_Logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20240118383580\/en\/808014\/5\/Tvardi-Master_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240118383580\/en\/808014\/22\/Tvardi-Master_Logo.jpg\"><\/a><\/p>\n<p>\n<b>Presentation Details:<br \/>\n<br \/><\/b>Date: Friday, January 19, 2024<br \/>\n<br \/>Time: 12:30 p.m. PST<br \/>\n<br \/>Location: Moscone West, San Francisco, CA<br \/>\n<br \/>Session Type: Trials in Progress Poster Session<br \/>\n<br \/>Abstract Title: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F229411&amp;esheet=53884882&amp;newsitemid=20240118383580&amp;lan=en-US&amp;anchor=A+Phase+1b%2F2+Study+to+Evaluate+the+Safety+and+Efficacy+of+TTI-101+as+Monotherapy+and+in+Combination+in+Advanced+Hepatocellular+Carcinoma&amp;index=1&amp;md5=ea1c6f7ba0619f33588db2c3c9b427bd\" rel=\"nofollow noopener\" shape=\"rect\">A Phase 1b\/2 Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Advanced Hepatocellular Carcinoma<\/a><br \/>Abstract #: TPS577<br \/>\n<br \/>Poster Bd #: P6<\/p>\n<p>\nThe REVERT <sub>LIVER CANCER<\/sub> trial is currently enrolling HCC patients at top US cancer research institutes and is designed to evaluate TTI-101 across multiple lines of therapy:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTTI-101 alone for patients previously treated with up to three prior lines of systemic therapy<\/li>\n<li>\nTTI-101 in combination with pembrolizumab (Keytruda\u00ae) for patients previously treated with immunotherapy<\/li>\n<li>\nTTI-101 in combination with atezolizumab (Tecentriq\u00ae) and bevacizumab (Avastin\u00ae) for treatment-na\u00efve patients<\/li>\n<\/ul>\n<p>\nHCC is the most common form of liver cancer; however, treatment options for the disease are limited and overall prognosis is poor, with a 5-year survival rate of 18%. TTI-101\u2019s target, STAT3, is a key regulatory protein which plays a critical role in the pathogenesis of HCC by initiating tumorigenesis as well as promoting an immunosuppressive tumor microenvironment. TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3.<\/p>\n<p>\n\u201c<!-- no quote -->We are excited to present this unique trial design that allows us to evaluate the potential of TTI-101 to enhance outcomes across 1<sup>st<\/sup>, 2<sup>nd<\/sup>, and last line HCC patients, where the current standard of care is insufficient,\u201d said Imran Alibhai, PhD, CEO of Tvardi Therapeutics.<\/p>\n<p>\nFor more information about the REVERT <sub>LIVER CANCER<\/sub> trial, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05440708&amp;esheet=53884882&amp;newsitemid=20240118383580&amp;lan=en-US&amp;anchor=ClinicalTrials.gov+%28NCT05440708%29&amp;index=2&amp;md5=b68866bcbe1369f190cbd72d8c4dfee0\" rel=\"nofollow noopener\" shape=\"rect\">ClinicalTrials.gov (NCT05440708)<\/a>.<\/p>\n<p>\n<b>About Tvardi Therapeutics<\/b><\/p>\n<p>\nTvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company has now initiated three Phase 2 clinical programs in STAT3-driven diseases: hepatocellular carcinoma (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05440708&amp;esheet=53884882&amp;newsitemid=20240118383580&amp;lan=en-US&amp;anchor=NCT05440708&amp;index=3&amp;md5=1b8d0cfe0e40380b2e314adb40670930\" rel=\"nofollow noopener\" shape=\"rect\">NCT05440708<\/a>), metastatic breast cancer (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05384119&amp;esheet=53884882&amp;newsitemid=20240118383580&amp;lan=en-US&amp;anchor=NCT05384119&amp;index=4&amp;md5=ccd33f5fa32d4d1bcf5c17dfaf840cd9\" rel=\"nofollow noopener\" shape=\"rect\">NCT05384119<\/a>), and idiopathic pulmonary fibrosis (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05671835&amp;esheet=53884882&amp;newsitemid=20240118383580&amp;lan=en-US&amp;anchor=NCT05671835&amp;index=5&amp;md5=fa885d39eb48caa3a93091b6169e8299\" rel=\"nofollow noopener\" shape=\"rect\">NCT05671835<\/a>). To learn more, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftvarditherapeutics.com%2F&amp;esheet=53884882&amp;newsitemid=20240118383580&amp;lan=en-US&amp;anchor=tvardi.com&amp;index=6&amp;md5=823e47e79ccce94f6aff7de83286567f\" rel=\"nofollow noopener\" shape=\"rect\">tvardi.com<\/a> or follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ftvardi%2Fabout&amp;esheet=53884882&amp;newsitemid=20240118383580&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=b6e211a6b4403d500fdca5eea68396ac\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Ftvarditherap&amp;esheet=53884882&amp;newsitemid=20240118383580&amp;lan=en-US&amp;anchor=X+%28Twitter%29&amp;index=8&amp;md5=c7112c5705fc211e3ea9028d1fa5720f\" rel=\"nofollow noopener\" shape=\"rect\">X (Twitter)<\/a>.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nTvardi Investor Relations<br \/>\n<br \/>Sara Manning<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#x6f;:&#105;&#x72;&#64;&#x74;v&#x61;r&#100;&#x69;&#46;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">ir&#64;t&#118;&#97;&#114;&#100;&#105;&#x2e;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>HOUSTON&#8211;(BUSINESS WIRE)&#8211;#BreastCancer&#8211;Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will present a trials in progress poster at the upcoming 2024 ASCO Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in San Francisco, CA. The poster will highlight the design of the ongoing REVERT LIVER CANCER &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58740","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"HOUSTON&#8211;(BUSINESS WIRE)&#8211;#BreastCancer&#8211;Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will present a trials in progress poster at the upcoming 2024 ASCO Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in San Francisco, CA. The poster will highlight the design of the ongoing REVERT LIVER CANCER ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-18T18:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240118383580\/en\/808014\/21\/Tvardi-Master_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium\",\"datePublished\":\"2024-01-18T18:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/\"},\"wordCount\":462,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240118383580\\\/en\\\/808014\\\/21\\\/Tvardi-Master_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/\",\"name\":\"Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240118383580\\\/en\\\/808014\\\/21\\\/Tvardi-Master_Logo.jpg\",\"datePublished\":\"2024-01-18T18:03:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240118383580\\\/en\\\/808014\\\/21\\\/Tvardi-Master_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240118383580\\\/en\\\/808014\\\/21\\\/Tvardi-Master_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium - Pharma Trend","og_description":"HOUSTON&#8211;(BUSINESS WIRE)&#8211;#BreastCancer&#8211;Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will present a trials in progress poster at the upcoming 2024 ASCO Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in San Francisco, CA. The poster will highlight the design of the ongoing REVERT LIVER CANCER ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/","og_site_name":"Pharma Trend","article_published_time":"2024-01-18T18:03:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240118383580\/en\/808014\/21\/Tvardi-Master_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium","datePublished":"2024-01-18T18:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/"},"wordCount":462,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240118383580\/en\/808014\/21\/Tvardi-Master_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/","url":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/","name":"Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240118383580\/en\/808014\/21\/Tvardi-Master_Logo.jpg","datePublished":"2024-01-18T18:03:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240118383580\/en\/808014\/21\/Tvardi-Master_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240118383580\/en\/808014\/21\/Tvardi-Master_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tvardi-therapeutics-announces-presentation-of-revert-liver-cancer-phase-2-clinical-trial-using-tti-101-a-novel-stat3-inhibitor-at-2024-asco-gastrointestinal-cancers-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58740"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58740\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}